Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UPDATE1: Takeda seeks gov't OK for Moderna COVID-19 vaccine in Japan

03/05/2021 | 03:38am EDT

Takeda Pharmaceutical Co. said Friday it has filed a request with Japan's health ministry for the approval of U.S. biotechnology company Moderna Inc.'s COVID-19 vaccine in the country.

It is the third application for regulatory approval of a COVID-19 vaccine in Japan, following U.S. pharmaceutical giant Pfizer Inc. and Britain'sAstraZeneca Plc.

Takeda is Moderna's partner for the clinical study, importation and distribution of the vaccine in Japan.

Under an agreement with the Japanese government, Takeda plans to supply 50 million doses of the Moderna vaccine, enough for 25 million people.

The Ministry of Health, Labor and Welfare is expected to process the application by examining data from clinical studies conducted in Japan and the United States.

Inoculations in Japan began last month, starting with Pfizer's vaccine for front-line health care workers.

The Moderna vaccine needs to be administered in two doses 28 days apart. It can be stored for about six months at around minus 20 C and is easier to handle than Pfizer's vaccine, which has to be kept at around minus 75 C for long-term storage.

Japan has signed agreements with Pfizer, AstraZeneca and Moderna for a total of 314 million doses of COVID-19 vaccine, enough to inoculate 157 million people. The country's population is around 126 million.

Ahead of the Tokyo Olympics and Paralympics, postponed for one year to this summer, Japan is still struggling to rein in infections in urban areas such as Tokyo where the COVID-19 state of emergency is set to be extended for two weeks beyond Sunday.

==Kyodo

© Kyodo News International, Inc., source Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.53% 7613 Delayed Quote.2.32%
MODERNA, INC. -3.17% 156.78 Delayed Quote.54.98%
PFIZER, INC. 0.26% 39.03 Delayed Quote.5.76%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.86% 3674 End-of-day quote.-2.16%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
04/18Takeda Pharmaceutical to Redeem $200 Million of 2.45% Senior Bonds Due 2022
MT
04/14CENTOGENE N  : Extends Diagnostics Testing Partnership With Takeda
MT
04/08Japan shares slip on coronavirus concerns
RE
04/07Japan stocks fall on virus woes, but M&As lift some industrials
RE
04/07TAKEDA PHARMACEUTICAL  : to Host Wave 1 Pipeline Market Opportunity Conference C..
AQ
04/07Kamada Amends GLASSIA License Contract with Takeda
MT
04/06STREET COLOR : Takeda Pharmaceutical Reportedly Suspends Development of Plasma T..
MT
04/05Japanese shares fall on profit booking, checking U.S. rates
RE
04/05SECTOR UPDATE : Health Care Stocks Scratch Out Slim Gains
MT
04/05UPDATE : Molecular Templates Scraps Experimental MT-3724 Drug, Takes Over Takeda..
MT
More news
Financials
Sales 2021 3 216 B 29 731 M 29 731 M
Net income 2021 271 B 2 504 M 2 504 M
Net Debt 2021 4 080 B 37 727 M 37 727 M
P/E ratio 2021 24,3x
Yield 2021 4,90%
Capitalization 5 748 B 53 158 M 53 148 M
EV / Sales 2021 3,06x
EV / Sales 2022 2,89x
Nbr of Employees 47 495
Free-Float 99,0%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 5 122,86 JPY
Last Close Price 3 674,00 JPY
Spread / Highest target 87,8%
Spread / Average Target 39,4%
Spread / Lowest Target 11,6%
EPS Revisions
Managers and Directors
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Mwana Lugogo Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-2.16%53 158
JOHNSON & JOHNSON5.78%438 293
ROCHE HOLDING AG0.42%290 135
PFIZER, INC.5.76%217 716
MERCK & CO., INC.-3.95%198 884
NOVARTIS AG-3.24%198 172